menu
    • menu

    Company profile for Scynexis

    NEW Drugs in Dev: 8
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    We are committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by developing innovative therapies. We believe that our lead compound, Ibrexafungerp (formerly SCY-078), has the potential to be an essential therapy in the treatment of multiple serious fungal infections, including vulvovaginal candidiasis, invasive candidiasis, invasive aspergillosis and refr...
    We are committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by developing innovative therapies. We believe that our lead compound, Ibrexafungerp (formerly SCY-078), has the potential to be an essential therapy in the treatment of multiple serious fungal infections, including vulvovaginal candidiasis, invasive candidiasis, invasive aspergillosis and refractory invasive fungal infections.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    ScynexisUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    1 Evertrust Plaza 13th Floor Jersey City, NJ 07302
    Telephone
    Telephone
    (201) 884-5485
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.scynexis.com/
    Linkedin
    Linkedin
    https://in.linkedin.com/company/scynexis
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    AMWC Asia-TDAC

    AMWC Asia-TDAC

    Not Confirmed

    envelop Contact Supplier

    AMWC Asia-TDAC

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    SCYNEXIS Announces $40.0 Million Private Placement
    SCYNEXIS Announces $40.0 Million Private Placement

    31 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/31/3265281/0/en/SCYNEXIS-Announces-40-0-Million-Private-Placement.html

    GLOBENEWSWIRE
    31 Mar 2026
    Share Share
    SCYNEXIS Complete Acquisition of PXL-770 AMPK Activator for ADPKD
    SCYNEXIS Complete Acquisition of PXL-770 AMPK Activator for ADPKD

    31 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/31/3265277/0/en/SCYNEXIS-Completes-Transformative-Acquisition-of-PXL-770-an-innovative-highly-selective-direct-AMPK-activator-for-the-Treatment-of-Autosomal-Dominant-Polycystic-Kidney-Disease-ADPK.html

    GLOBENEWSWIRE
    31 Mar 2026
    Share Share
    SCYNEXIS Reveals 2025 Financials And Corporate Update
    SCYNEXIS Reveals 2025 Financials And Corporate Update

    04 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/04/3249748/0/en/SCYNEXIS-Reports-Full-Year-2025-Financial-Results-and-Provides-Corporate-Update.html

    GLOBENEWSWIRE
    04 Mar 2026
    Share Share
    SCYNEXIS Initiates Phase 1 Trial For Intravenous SCY-247
    SCYNEXIS Initiates Phase 1 Trial For Intravenous SCY-247

    26 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/26/3245564/0/en/SCYNEXIS-Announces-First-Participants-Dosed-in-a-Phase-1-Single-Ascending-Dose-and-Multiple-Ascending-Dose-Trial-of-Intravenous-SCY-247.html

    GLOBENEWSWIRE
    26 Feb 2026
    Share Share
    SCYNEXIS Showcases SCY-247's Antifungal Activity at IMARI
    SCYNEXIS Showcases SCY-247's Antifungal Activity at IMARI

    28 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/28/3227560/0/en/SCYNEXIS-Announces-Presentations-Highlighting-the-Potent-Antifungal-Activity-of-its-Second-Generation-Fungerp-SCY-247-Against-Drug-Resistant-Fungi-at-the-Inaugural-Interdisciplinar.html

    GLOBENEWSWIRE
    28 Jan 2026
    Share Share
    SCYNEXIS Gets FDA (QIDP) & Fast Track Designations For SCY-247
    SCYNEXIS Gets FDA (QIDP) & Fast Track Designations For SCY-247

    21 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/21/3222722/0/en/SCYNEXIS-Receives-FDA-Qualified-Infectious-Disease-Product-QIDP-and-Fast-Track-Designations-for-SCY-247.html

    GLOBENEWSWIRE
    21 Jan 2026
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search